DMP 266 study opens at Jefferson. Clearinghouse, AIDS Newsletter Database, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5714. A fee will apply.

Important note: Information in this article was accurate in 1997. The state of the art may have changed since the publication date.

DMP 266 study opens at Jefferson. Clearinghouse, AIDS Newsletter Database, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5714. A fee will apply.

Crit Path AIDS Proj. 1997 Summer;(No 32):30-1. Unique Identifier : AIDSLINE MED/97702730

Abstract: Dupont Merck announced that its experimental non-nucleoside reverse transcriptase inhibitor DMP 266 has shown viral load reductions to undetectable levels in eighty percent of study subjects. CD4 counts also increased among the study group. Other studies are underway to study DMP 266 at higher dosages and in combination with other drugs. Enrollment information is included.

Keywords: *Drugs, Investigational *Oxazines/ADMINISTRATION & DOSAGE *Reverse Transcriptase Inhibitors/ADMINISTRATION & DOSAGE
971230
M97C1586

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1997. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1997. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .